These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 35641483)

  • 1. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer.
    Wang Q; Bergholz JS; Ding L; Lin Z; Kabraji SK; Hughes ME; He X; Xie S; Jiang T; Wang W; Zoeller JJ; Kim HJ; Roberts TM; Konstantinopoulos PA; Matulonis UA; Dillon DA; Winer EP; Lin NU; Zhao JJ
    Nat Commun; 2022 May; 13(1):3022. PubMed ID: 35641483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
    Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
    Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F
    Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
    Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 7. BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers.
    Lei G; Mao C; Horbath AD; Yan Y; Cai S; Yao J; Jiang Y; Sun M; Liu X; Cheng J; Xu Z; Lee H; Li Q; Lu Z; Zhuang L; Chen MK; Alapati A; Yap TA; Hung MC; You MJ; Piwnica-Worms H; Gan B
    Cancer Discov; 2024 Aug; 14(8):1476-1495. PubMed ID: 38552003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
    Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer.
    Tai Y; Chow A; Han S; Coker C; Ma W; Gu Y; Estrada Navarro V; Kandpal M; Hibshoosh H; Kalinsky K; Manova-Todorova K; Safonov A; Walsh EM; Robson M; Norton L; Baer R; Merghoub T; Biswas AK; Acharyya S
    EMBO Mol Med; 2024 Aug; 16(8):1957-1980. PubMed ID: 38956205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancer.
    Li X; Poire A; Jeong KJ; Zhang D; Ozmen TY; Chen G; Sun C; Mills GB
    Nat Commun; 2024 May; 15(1):4485. PubMed ID: 38802355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells.
    Alvarado-Cruz I; Mahmoud M; Khan M; Zhao S; Oeck S; Meas R; Clairmont K; Quintana V; Zhu Y; Porciuncula A; Wyatt H; Ma S; Shyr Y; Kong Y; LoRusso PM; Laverty D; Nagel ZD; Schalper KA; Krauthammer M; Sweasy JB
    Biochem Pharmacol; 2021 Feb; 184():114359. PubMed ID: 33285109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.
    Mehta AK; Cheney EM; Hartl CA; Pantelidou C; Oliwa M; Castrillon JA; Lin JR; Hurst KE; de Oliveira Taveira M; Johnson NT; Oldham WM; Kalocsay M; Berberich MJ; Boswell SA; Kothari A; Johnson S; Dillon DA; Lipschitz M; Rodig S; Santagata S; Garber JE; Tung N; Yélamos J; Thaxton JE; Mittendorf EA; Sorger PK; Shapiro GI; Guerriero JL
    Nat Cancer; 2021 Jan; 2(1):66-82. PubMed ID: 33738458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
    Ciccone MA; Adams CL; Bowen C; Thakur T; Ricker C; Culver JO; Maoz A; Melas M; Idos GE; Jeyasekharan AD; Matsuo K; Roman LD; Gruber SB; McDonnell KJ
    Gynecol Oncol; 2020 Dec; 159(3):869-876. PubMed ID: 33032822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resurrection of PARP Inhibitors in Breast Cancer.
    Lyons TG; Robson ME
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.
    Chen MK
    FEBS J; 2021 May; 288(9):2884-2887. PubMed ID: 33570247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
    Shen J; Zhao W; Ju Z; Wang L; Peng Y; Labrie M; Yap TA; Mills GB; Peng G
    Cancer Res; 2019 Jan; 79(2):311-319. PubMed ID: 30482774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
    Clark CC; Weitzel JN; O'Connor TR
    Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 53BP1 loss elicits cGAS-STING-dependent antitumor immunity in ovarian and pancreatic cancer.
    Sun Y; Patterson-Fortin J; Han S; Li Z; Nowicka Z; Hirohashi Y; Kilgas S; Yi JK; Spektor A; Fendler W; Konstantinopoulos PA; Chowdhury D
    Nat Commun; 2024 Aug; 15(1):6676. PubMed ID: 39107288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.